CIK 0001281895
- Non-accelerated filer
- Smaller reporting company
ROCKET PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RCKT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 646-440-9100
- Business address
- 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
- Former names
- INOTEK PHARMACEUTICALS CORP
- 4 Open-market sale See Remarks sold 2,545 shares at $2.98 ($7,592)
- 4 Open-market sale See Remarks sold 1,086 shares at $2.98 ($3,240)
- 4 Open-market sale CEO sold 6,276 shares at $2.98 ($18,721)
- 4 Open-market sale General Counsel sold 1,646 shares at $2.98 ($4,910)
- 4 Grant or award General Counsel acquired 100,000 shares (grant or award)
- 4 Open-market sale See Remarks sold 28,918 shares at an average $3.96 ($114,581)
- 4 Grant or award Chief Medical Officer acquired 345,911 shares (grant or award)
- 4 Grant or award Director acquired 53,333 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Option exercise Director acquired 1,100,000 shares (option exercise)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award See Remarks acquired 40,000 shares (grant or award)
- 4 Grant or award General Counsel acquired 150,000 shares (grant or award)
- 4 Grant or award See Remarks acquired 80,000 shares (grant or award)
- 4 Open-market buy Director bought 10,000 shares at $3.41 ($34,100)
- 4 Open-market sale See Remarks sold 1,060 shares at an average $3.04 ($3,224)
- 4 Open-market sale See Remarks sold 2,485 shares at an average $3.04 ($7,561)
- 4 Open-market sale General Counsel sold 1,592 shares at an average $3.04 ($4,839)
- 4 Shares withheld for taxes CEO gave up 2,234 shares (to pay taxes)
- 4 Open-market sale See Remarks sold 11,161 shares at $3.02 ($33,695)
Page 3 of 21 · 406 filings